HUP0003349A2 - Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents

Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk

Info

Publication number
HUP0003349A2
HUP0003349A2 HU0003349A HUP0003349A HUP0003349A2 HU P0003349 A2 HUP0003349 A2 HU P0003349A2 HU 0003349 A HU0003349 A HU 0003349A HU P0003349 A HUP0003349 A HU P0003349A HU P0003349 A2 HUP0003349 A2 HU P0003349A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
parathyroid hormone
hormone analogs
peptide
peptide parathyroid
Prior art date
Application number
HU0003349A
Other languages
English (en)
Inventor
Stephen M. Condon
Isabelle Morize
Original Assignee
Aventis Pharmaceuticals Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Products Inc. filed Critical Aventis Pharmaceuticals Products Inc.
Publication of HUP0003349A2 publication Critical patent/HUP0003349A2/hu
Publication of HUP0003349A3 publication Critical patent/HUP0003349A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Atalálmány tárgya a hPTH(1-34) és hPTHrP(1-34) ciklikus és aciklikuspeptidanalógjai, az ilyen peptidvegyületeket tartalmazó gyógyászatikészítmények, valamint a találmány szerinti peptidvegyületekalkalmazása. Avegyületek alkalmasak a szervezet kalcium-anyagcseréjének szabályozásával összefüggő fiziológiai állapotokkezelésére. Ó
HU0003349A 1997-05-14 1998-05-13 Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use HUP0003349A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4647297P 1997-05-14 1997-05-14

Publications (2)

Publication Number Publication Date
HUP0003349A2 true HUP0003349A2 (hu) 2001-01-29
HUP0003349A3 HUP0003349A3 (en) 2001-12-28

Family

ID=21943653

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003349A HUP0003349A3 (en) 1997-05-14 1998-05-13 Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use

Country Status (20)

Country Link
US (2) US6472505B1 (hu)
EP (1) EP0986395A4 (hu)
JP (1) JP2001517957A (hu)
KR (1) KR100351213B1 (hu)
CN (1) CN1261281A (hu)
AP (1) AP9901686A0 (hu)
AU (1) AU746461B2 (hu)
BG (1) BG103957A (hu)
BR (1) BR9808786A (hu)
CA (1) CA2290443A1 (hu)
EA (1) EA002819B1 (hu)
HU (1) HUP0003349A3 (hu)
IL (1) IL132901A0 (hu)
NO (1) NO995568L (hu)
OA (1) OA11216A (hu)
PL (1) PL336803A1 (hu)
SK (1) SK151599A3 (hu)
UA (1) UA62967C2 (hu)
WO (1) WO1998051324A1 (hu)
ZA (1) ZA984077B (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL347103A1 (en) * 1998-04-15 2002-03-25 Aventis Pharm Prod Inc Process for the preparation of resin-bound cyclic peptides
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
AU2003233286A1 (en) * 2002-05-16 2003-12-02 Theratechnologies Inc. Pth derivatives resistant to skin proteases
WO2004073587A2 (en) * 2003-02-19 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
BRPI0412664A (pt) * 2003-07-15 2006-09-26 Ca Nat Research Council método para tratar uma condição caracterizada por hiperproliferação de células da pele em um indivìduo em risco ou portador dessa condição e utilização de uma quantidade terapeuticamente efetiva de um análogo cìclico de hormÈnio de paratireóide humano (hpth)
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
EP1904526A4 (en) 2005-07-07 2009-10-28 Fulcrum Sp Ltd SP1-POLYPEPTIDES, MODIFIED SP1-POLYPEPTIDES AND APPLICATIONS THEREOF
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US7820179B2 (en) * 2006-10-13 2010-10-26 Eli Lilly And Company Pegylated PTH as PTH receptor modulators and uses thereof
WO2010086867A2 (en) 2009-02-02 2010-08-05 Ramot At Tel Aviv University Ltd. Peptides, pharmaceutical compositions comprising same and uses thereof
US8912142B2 (en) 2009-04-01 2014-12-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
TWI520744B (zh) 2009-07-29 2016-02-11 凱宜製藥股份有限公司 減少副甲狀腺素量之治療劑
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2566500B1 (en) 2010-05-05 2017-04-12 Rappaport Family Institute for Research in the Medical Sciences Ccl1 for use in therapy
RU2604809C2 (ru) * 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Аналоги паратиреоидного гормона и их применение
EP2600885A2 (en) 2010-08-04 2013-06-12 Ramot at Tel Aviv University, Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
ES2702487T3 (es) * 2011-06-17 2019-03-01 Nantenergy Inc Líquido iónico que contiene iones sulfonato
RU2630301C2 (ru) 2012-03-06 2017-09-06 Сэллект Байотерапьютикс Лтд Устройства и способы для отбора клеток, устойчивых к апоптотическим сигналам, и области их применения
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
WO2015145449A2 (en) 2014-03-27 2015-10-01 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
EP3261582B1 (en) 2015-02-26 2021-01-06 Remodeless CV Ltd. Methods and compositions relating to leptin antagonists
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
US11820833B2 (en) 2016-06-05 2023-11-21 Tel Hashomer Medical Research Infrastructure And Services Ltd. Peptides that inhibit binding of EPCR to its ligand to treat inflammation
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
CN109689120A (zh) 2016-12-01 2019-04-26 拉莫特特拉维夫大学有限公司 用于神经损伤的联合治疗
EP3606615A1 (en) 2017-04-07 2020-02-12 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Hair care compositions
US20200172604A1 (en) 2017-05-23 2020-06-04 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
US11660270B2 (en) 2017-07-20 2023-05-30 Indiana University Research And Technology Corporation Nanoparticle compositions
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
US20200390800A1 (en) 2017-11-29 2020-12-17 Ramot At Tel-Aviv University Ltd. Methods of preventing or treating neurogenic shock
KR20210044220A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
BR112022000319A2 (pt) 2019-07-11 2022-03-15 Kahr Medical Ltd Heterodímeros e métodos de uso dos mesmos
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
JP2023513334A (ja) 2020-02-09 2023-03-30 エヌエルシー ファーマ リミテッド Ｓａｒｓ－ｃｏｖ－２の迅速検出検査
IL296230A (en) 2020-03-05 2022-11-01 Ariel Scient Innovations Ltd preparations to stop bleeding
US20230127559A1 (en) 2020-03-16 2023-04-27 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
EP4217370A2 (en) 2020-09-23 2023-08-02 Yeda Research and Development Co. Ltd Methods and compositions for treating coronaviral infections
EP4225903A1 (en) 2020-10-07 2023-08-16 Protalix Ltd. Long-acting dnase
CN117098559A (zh) 2020-11-03 2023-11-21 波塔力克斯有限公司 修饰的尿酸酶及其用途
CA3208982A1 (en) 2021-02-18 2022-08-25 Ravid STRAUSSMAN Method of generating vaccines
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
WO2023031934A1 (en) 2021-09-02 2023-03-09 Yeda Research And Development Co. Ltd. Agents that target the glycine arginine-rich domain of nucleolin and uses thereof
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4427827A (en) 1982-10-20 1984-01-24 Usv Pharmaceutical Corporation Synthesis of hormone fragments
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
CA2087087C (en) 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
CA2098639A1 (en) 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE19508672A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
DE69629758T2 (de) 1995-06-07 2004-06-03 Compaq Computer Corp., Houston Verfahren und Vorrichtung für die Überwachung des Datenflusses in einem fehlertoleranten Multiprozessorsystem
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
ES2207740T3 (es) * 1996-08-02 2004-06-01 National Research Council Of Canada Analogo de la hormona paratiroide para el tratamiento de la osteoporosis.

Also Published As

Publication number Publication date
AU7386798A (en) 1998-12-08
KR100351213B1 (ko) 2002-09-05
ZA984077B (en) 1998-11-24
WO1998051324A1 (en) 1998-11-19
AP9901686A0 (en) 1999-12-31
KR20010012568A (ko) 2001-02-15
SK151599A3 (en) 2000-09-12
US6472505B1 (en) 2002-10-29
HUP0003349A3 (en) 2001-12-28
BR9808786A (pt) 2000-07-11
EP0986395A4 (en) 2004-12-01
CA2290443A1 (en) 1998-11-19
PL336803A1 (en) 2000-07-17
OA11216A (en) 2003-07-10
UA62967C2 (en) 2004-01-15
US20020132973A1 (en) 2002-09-19
IL132901A0 (en) 2001-03-19
NO995568D0 (no) 1999-11-12
EA002819B1 (ru) 2002-10-31
CN1261281A (zh) 2000-07-26
JP2001517957A (ja) 2001-10-09
BG103957A (bg) 2000-04-28
EA199901025A1 (ru) 2000-06-26
EP0986395A1 (en) 2000-03-22
AU746461B2 (en) 2002-05-02
NO995568L (no) 1999-12-29

Similar Documents

Publication Publication Date Title
HUP0003349A2 (hu) Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
MY121291A (en) Fracture healing using pthrp analogs
EA200501744A1 (ru) Пептид (варианты), содержащая его композиция и лекарственный препарат для профилактики и лечения астеросклероза
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
HUP0000432A2 (hu) Inzulin C-peptidek
ATE273693T1 (de) Proteinhaltige arzneimittel
IL116499A0 (en) Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
DE69838647D1 (de) Behandlung von fettleibigkeit
GEP20033095B (en) Parathyroid Hormone Analogues for the Treatment of Osteoporosis
KR960702847A (ko) 생물학적 활성의 바소프레신 유사체
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
AR036591A1 (es) Uso de la hl en hiperestimulacion ovarica controlada
ATE245998T1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
IL120503A0 (en) Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
EP0821004A4 (en) NOVEL PEPTIDES AND MEDICINES FOR BONE DISEASES CONTAINING THESE PEPTIDES AS ACTIVE INGREDIENT
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
CY1108402T1 (el) Φαρμακευτικο μεσο που περιεχει μια αντιφλεγμονωδη δραστικη ουσια και υδρολυμα λακταλβουμινης και χρηση αυτου
IL114460A0 (en) Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
ZA9510828B (en) Peptide p277 analogs and phamarceutical compositions comprising them for treatment or diagnosis of diabetes
BR1100653A (pt) Análogos de hormÈnio de paratiróide e peptìdeo relacionado com hormÈnio de paratiróide: sìntese e uso para o tratamento de osteoporose
MX9707904A (es) Analogos del factor de liberacion de la hormona del crecimiento.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees